Market access has become a focus for nearly every multinational pharmaceutical, medical device, and diagnostics company. In recent years, some have even created a functional executive to drive market access initiatives both internally and externally. While the growing importance of…
With financial pressures mounting for key payers in Brazil’s healthcare space (pressures that are unlikely to go away given the country’s economic outlook and demographic transition), multinational healthcare companies have shown that they will prioritize two strategies for overcoming market…
Last week in São Paulo, FSG hosted a workshop session for its healthcare cohort. The event, focused on the Brazil healthcare sector, was designed to identify current opportunities and risks while also establishing a consensus view on the future drivers…
To recap from our last post on the Brazilian healthcare system, the country witnessed 6.5% (CAGR) growth in total spending on healthcare between 2003 and 2014, only to see spending contract by a forecasted -2.9% (CAGR) during the 2015-2016 period.…
Brazil’s healthcare system is at an inflection point. After growing by an average of 7.5% (in real local currency terms) between 2003 and 2014, FSG forecasts that Brazil’s healthcare spending contracted on average by -2.5% between 2015 and 2016. This…
This month, Frontier Strategy Group hosted an event for regional Latin America executives from the pharmaceutical and medical device industries. The event focused on how healthcare multinationals can respond to changing economic conditions across Latin America. Below are the key…
This March in Miami, senior executives from leading healthcare multinational companies gathered for a debate and discussion session moderated by Frontier Strategy Group. The Miami Healthcare Breakfast Roundtable provided a unique opportunity for senior executives in the pharmaceutical and medical…